2Borden EC, Lotan R, Levens D, et al. Differentiation therapy of cancer: Laboratory and clinical investigations. Cancer Res,1993, 53:4109-4115.
3Bello D, Webber MM, Kleinman HK, et al. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis, 1997, 18:1215-1223.
4Rhim JS, Webber MM, Bello D, et al. Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci USA, 1994, 91:11874-11878.
5Webber MM, Bello D, Kleinman HK, et al. Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line.Carcinogenesis, 1996,17:1641-1646.
6Bauer JJ, Sesterhenn IA, Mostofi KF, et al. p53 nuclear prorein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res , 1995,1:1295-1300.
7Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. JNatl Cancer Inst, 1993,85:1657-1669.
8Aprikian AG, Sarkis AS, Fair WR, et al. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol, 1994, 151:1276-1280.
9Eastham JA, Stapleton AM, Gousse AE, et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res, 1995,1:1111-1118.
10Heidenberg HB, Bauer JJ, McLeod DG, et al. The role of the p53 tumor suppressor gene in prostate cancer:A possible biomarker? Urology, 1996,48: 971-979.
8Leung TW,Xue WC,Cheung AN. Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix[J].Gynecol Oneol,2004,(03):866-872.
9Small EJ,Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age[J].Journal Of Urology,2006,(06):66-71.
10Lucas A,Petrylak DP. The case for early chemotherapy for the treatmeat of metastatic disease[J].Journal Of Urology,2006,(06):72-75.
